Chimera BioEngineering

Organization Address
499 Illinois Street
San Francisco, CA 94158

Organization Phone
(310) 497-0736


Biotech and Pharmaceutical

Organization Description
Chimera Bioengineering is a biotherapeutics company focused on building control systems for chimeric antigen receptor (CAR) T cell therapeutics. CAR Ts are a new class of persistent, personal and living immunotherapies with impressive Phase 1/2 clinical trial results of 80-90% complete responses in relapsed/refractory B cell malignancies. This has led to significant interest on CAR T as a novel therapeutic modality. But while promising, toxicity, both acute (cytokine release syndrome) and off-tumor/on-target autoimmunity, remains a significant hurdle for the widespread adoption of CAR Ts. And while treatment of B cell malignancies have heralded success, in part because patients can live with B aplasia, expanding the disease horizon of CAR Ts to all other cancers will require solving the toxicity problem. Chimera solves toxicity of CAR T cells with a “volume knob” gene expression control system that responds to exogenously dosed small molecule ligands. These customized, modular, gene regulatory switches, with technology originally developed at Caltech, operate post-transcriptionally, perform fast, at therapeutic ligand concentrations and are non-immunogenic and durable. Because the switch technology is extensible to many different, bio-orthogonal small molecules, a pipeline of switches can be built and deployed individually or for combination therapy (multiple antigen targeting,). The switches snap into all existing CAR transgenes during the standard ex vivo CAR manufacturing process.